Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Drug Discount Program Hits A Turning Point, But In Which Direction?

This article was originally published in RPM Report

Executive Summary

Long-awaited “mega-guidance” sets boundaries on discount and makes big changes for HIV drugs – and could mean the beginning of the end of the scrutiny of the program. A legislative proposal floated in the context of the “21st Century Cures” bill might move things in a different direction.

You may also be interested in...



Tuning Up Part D Amid Drug Pricing Debate; MedPAC Likely To Urge More Flexibility For Plans Setting Formularies

The Medicare Payment Advisory Committee (MedPAC) will be moving forward with specific recommendations to improve prescription drug provisions under Part D and Part B – but is not ready to take the lead on policy development addressing prescription drug prices overall.

Goodbye ‘340B,’ Hello ‘Outpatient Drug Discount Program’ In House Reform Bill

House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.

Price Controls in Action: Understanding the Rise of the 340B Program

The health care reform law dramatically expanded the number of entities eligible to purchase drugs via the federally administered 340B program, while simultaneously increasing the size of the mandatory discounts given to covered entities. Manufacturers are understandably frustrated. Rather than hope for elimination of the program, however, they may be better served working within the system to contain its impact.

Topics

UsernamePublicRestriction

Register

PS079781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel